{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:54Z","timestamp":1787070834107,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Intravesical instillation of Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy remains the most effective adjuvant treatment for noninvasive bladder cancer. Systemic BCG-related complications are rare and usually related to infective agent or an immune-mediated reaction. We discussed a case with perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) vasculitis, developing after instillation of BCG for non-invasive bladder cancer. A 68-year-old man presented with nephritic syndrome a few months after BCG instillations which was performed for his non\u2013muscle-invasive bladder cancer adjuvant therapy. The renal function had declined slowly after the first instillation and urinary sediment reveals the new onset of nephritic proteinuria and hematuria. High titer of p-ANCA was present. His renal biopsy was consistent with acute renal vasculitis. The patient's creatinine level regressed with immunosuppressive therapy and he was clinically followed up without hemodialysis. Here, we presented a patient that diagnosed as p-ANCA related vasculitis occurred after BCG instillation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_890_20","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T03:13:21Z","timestamp":1623986001000},"page":"609-612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Bacillus Calmette\u2013Gu\u00e9rin-induced perinuclear antineutrophil cytoplasmic antibodies associated vasculitis in bladder cancer"],"prefix":"10.4103","volume":"17","author":[{"given":"Sibel Yucel","family":"Kocak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Kudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suheyla","family":"Apayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-54-20241021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0090-4295(91)80136-U","article-title":"Comparison of BCG with other intravesical agents","volume":"37","author":"Lamm","year":"1991","journal-title":"Urology"},{"key":"R2-54-20241021","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"J Urol"},{"key":"R3-54-20241021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette - Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"R4-54-20241021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10555-009-9195-6","article-title":"The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillusCalmette-Gu\u00e9rin (BCG) immuno-therapy for urothelial carcinoma of the bladder","volume":"28","author":"Rosevear","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"R5-54-20241021","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette - Gu\u00e9rin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"R6-54-20241021","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7863\/jum.2007.26.5.671","article-title":"Tuberculous epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma: Sonographic findings","volume":"26","author":"Salvador","year":"2007","journal-title":"J Ultrasound Med"},{"key":"R7-54-20241021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/ndt\/gfh688","article-title":"Acute renal failure following intravesical bacille Calmette Gu\u00e9rin chemotherapy for superficial carcinoma of the bladder","volume":"20","author":"Fry","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R8-54-20241021","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0090-4295(98)00499-3","article-title":"Granulomatous nephritis as a complication of intrarenal bacille Calmette - Gu\u00e9rin therapy","volume":"53","author":"Soda","year":"1999","journal-title":"Urology"},{"key":"R9-54-20241021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/1319-2442.225178","article-title":"A case of renal granulomatosis with polyangiitis following intravesical bacillus Calmette - Gu\u00e9rin therapy","volume":"29","author":"Selmi","year":"2018","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R10-54-20241021","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/00365540510035300","article-title":"Henoch-Sch\u00f6nlein purpura after intravesical administration of bacillus Calmette-Gu\u00e9rin","volume":"37","author":"Nan","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"R11-54-20241021","first-page":"481","article-title":"Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette - Gu\u00e9rin","volume":"22","author":"Granel","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R12-54-20241021","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette - Gu\u00e9rin (BCG) Infection following \u0131ntravesical BCG administration as adjunctive therapy for bladder cancer: Incidence, risk factors, and outcome in a single-\u0131nstitution series and review of the literature","volume":"938179","author":"As\u00edn","year":"2014","journal-title":"Medicine"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_890_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:23Z","timestamp":1787067443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_890_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_890_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}